@article{cf0abbfb8b01479c9ada9ba2a5dcc3ef,
title = "PPARs and LXRs: Atherosclerosis goes nuclear",
abstract = "Atherosclerosis is the leading cause of mortality in the Western world, and new therapeutics to target the metabolic and inflammatory factors that underlie its pathogenesis are needed. Peroxisome proliferator-activated receptors and liver X receptors are lipid-activated nuclear receptors that regulate systemic glucose and lipid metabolism, and modulate inflammation within the vascular wall. New understanding of their functions in physiology and the development of high-affinity synthetic ligands highlight their potential as targets for the treatment of cardiovascular disease.",
author = "Barish, {Grant D.} and Evans, {Ronald M.}",
note = "Funding Information: We thank Chih-Hao Lee and Yong-Xu Wang for helpful comments, William Alaynick, Helen Cho and Weimin He for critical reading of this manuscript, Lita Ong and Elaine Stevens for administrative support, and Jamie Simon for Figure 1 . G.D.B. is supported by the NIH Public Health Services grant CA09370-23. R.M.E. is an investigator of the Howard Hughes Medical Institute at the Salk Institute for Biological Studies and March of Dimes Chair in Molecular and Developmental Biology. This work was supported by the Howard Hughes Medical Institute, the Hilblom Foundation, the NIH NURSA orphan receptor program grant U19DK62434, and the NIH grant HD27183. We apologize to our colleagues that many primary references could not be included because of space limitations.",
year = "2004",
month = may,
doi = "10.1016/j.tem.2004.03.003",
language = "English (US)",
volume = "15",
pages = "158--165",
journal = "Trends in Endocrinology and Metabolism",
issn = "1043-2760",
publisher = "Elsevier Inc.",
number = "4",
}
